Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2001 Nov;92(11):1225–1234. doi: 10.1111/j.1349-7006.2001.tb02144.x

A Potential Use of a Synthetic Retinoid TAC‐101 as an Orally Active Agent That Blocks Angiogenesis in Liver Metastases of Human Stomach Cancer Cells

Tsutomu Oikawa 1,✉, Koji Murakami 2, Masaki Sano 2, Jiro Shibata 2, Konstanty Wierzba 2, Yuji Yamada 2
PMCID: PMC5926657  PMID: 11714448

Abstract

TAC‐101 (4‐[3,5‐bis(trimethylsilyl)benzamido]benzoic acid) is a novel, synthetic retinoid that is effective against liver metastases of human gastrointestinal cancer cells such as the human stomach carcinoma line AZ‐521 in animal models, and is currently in use in phase I cancer trials. However, the mechanism of its antimetastatic action is still poorly understood. Tumor metastasis depends on angiogenesis, and various retinoids have been found to exhibit antiangiogenic activity. Based on these findings we here examined the antiangiogenic effects of TAC‐101. Oral administration of TAC‐101 (2‐8 mg/kg/day) resulted in a drastic suppression of the AZ‐521 cell‐induced angiogenesis in a mouse dorsal air sac assay system, compared to the vehicle alone. Immunohistochemical analysis with antibody against the endothelial marker CD31 revealed a significant reduction in microvessel density in liver metastases from animals treated with TAC‐101 (8 mg/kg p.o.), compared to liver metastases from the untreated control animals. The ability of TAC‐101 (8 mg/kg p.o.) to prevent experimental liver metastasis of AZ‐521 cells in athymic nude mice was comparable with that of the known angiogenesis inhibitor TNP‐470 (30 mg/kg s.c.). TAC‐101 also affected angiogenesis in chorioallantoic membranes and some functions of endothelial cells associated with angiogenesis, whereas the retinoid failed to suppress AZ‐521 cell proliferation directly. These data suggest that the TAC‐101 is an orally active antiangiogenic agent and that this antiangiogenic property may contribute to its efficacy against liver metastasis of human stomach cancer cells.

Keywords: Antiangiogenic activity, TAC‐101, Synthetic retinoid, Antimetastatic activity, Angiostatic therapy

Full Text

The Full Text of this article is available as a PDF (2.8 MB).

REFERENCES

  • 1. ) Folkman , J. and Shing , Y.Angiogenesis . J. Biol. Chem 26710931 – 10934 ( 1992. ). [PubMed] [Google Scholar]
  • 2. ) Bouck , N. , Stellmach , V. and Hsu , S. C.How tumors become angiogenic . Adv. Cancer Res 69135 – 174 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Oikawa , T. , Hirotani , K. , Nakamura , O. , Shudo , K. , Hiragun , A. and Iwaguchi , T.A highly potent antiangiogenic activity of retinoids . Cancer Lett 48157 – 162 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Oikawa , T.Strategies to find novel angiogenesis inhibitors as potential therapeutic agents for cancer . Curr. Med. Chem 1 , 406 – 417 ( 1995. ). [Google Scholar]
  • 5. ) Ingber , D. and Folkman , J.Inhibition of angiogenesis through modulation of collagen metabolism . Lab. Invest 5944 – 51 ( 1988. ). [PubMed] [Google Scholar]
  • 6. ) Pienta , K. J. , Nguyen , N. M. and Lehr , J. E.Treatment of prostate cancer in the rat with the synthetic retinoid fenret‐inide . Cancer Res 53224 – 226 ( 1993. ). [PubMed] [Google Scholar]
  • 7. ) Majewski , S. , Marczak , M. , Szmurlo , A. , Jablonska , S. and Bollag , W.Retinoids, interferon a, 1,25‐dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non‐HPV‐harboring tumor cells: RARα mediates the anti‐angiogenic effect of retinoids . Cancer Lett 89117 – 124 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Liaudet‐Coopman , E. D. E. , Berchem , G. J. and Wellstein , A.In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinoma . Clin. Cancer Res 3179 – 184 ( 1997. ). [PubMed] [Google Scholar]
  • 9. ) Lingen , M. W. , Polverini , P. J. and Bouck , N. P.Retinoic acid and interferon α act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma . Cancer Res 58 , 5551 – 5558 ( 1998. ). [PubMed] [Google Scholar]
  • 10. ) Hashimoto , Y. , Kagechika , H. , Kawachi , E. , Fukasawa , H. , Saito , G. and Shudo , K.Evaluation of differentiation‐inducing activity of retinoids on human leukemia cell lines HL‐60 andNB4 . Biol. Pharm. Bull 19 , 1322 – 1328 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Murakami , K. , Wierzba , K. , Sano , M. , Shibata , J. , Yonekura , K. , Hashimoto , A. , Sato , K. and Yamada , Y.TAC‐101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life‐span . Clin. Exp. Metastasis 16 , 323 – 331 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Murakami , K. , Matsuura , T. , Sano , M. , Hashimoto , A. , Yonekura , K. , Sakukawa , R. , Yamada , Y. and Saiki , I.4‐[3,5‐Bis(trimethylsilyl)benzamido]benzoic acid (TAC‐101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life‐span of tumor‐bearing animals . Clin. Exp. Metastasis 16 , 633 – 643 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Sakukawa , R. , Murakami , K. , Ikeda , T. , Yamada , Y. and Saiki , I.Effect of 4‐[3,5‐bis(trimethylsilyl)benzamido]ben‐zoic acid (TAC‐101) on the liver metastasis of colon 26‐L5 carcinoma cells . Oncol. Res. 10 , 287 – 293 ( 1998. ). [PubMed] [Google Scholar]
  • 14. ) Oikawa , T. , Sasaki , M. , Inose , M. , Shimamura , M. , Kuboki , H. , Hirano , S. , Kumagai , H. , Ishizuka , M. and Takeuchi , T.Effects of cytogenin, a novel microbial product, on embryonic and tumor cell‐induced angiogenic responses in vivo . Anticancer Res 17 , 1881 – 1886 ( 1997. ). [PubMed] [Google Scholar]
  • 15. ) Shibata , J. , Murakami , K. , Abe , M. , Hashimoto , A. , Utsugi , T. , Fukushima , M. and Yamada , Y.Life prolonging effect of antitumor agents on postoperative adjuvant therapy in the lung spontaneous metastasis model in mice . Anticancer Res. 18 , 1203 – 1209 ( 1998. ). [PubMed] [Google Scholar]
  • 16. ) Ingber , D. , Fujita , T. , Kishimoto , S. , Sudo , K. , Kanamaru , T. , Brem , H. and Folkman , J.Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth . Nature , 348 , 555 – 557 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Nomura , T. , Sakurai , Y. and Inaba , M. “ The Nude Mouse and Anticancer Drug Evaluation ,“ pp. 29 – 52 ( 1996. ). Chemotherapy Publishers; , Tokyo . [Google Scholar]
  • 18. ) Oikawa , T. , Sasaki , T. , Nakamura , M. , Shimamura , M. , Tanahashi , N. , Oõmura , S. and Tanaka , K.The proteasome is involved in angiogenesis . Biochem. Biophys. Res. Com-mun 246 , 243 – 248 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Sato , Y. and Rifkin , D.Autocrine activities of basic fibro‐blast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis . J. Cell Biol 107 , 1199 – 1205 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. ) Vermeulen , P. B. , Gasparini , G. , Fox , S. B. , Toi , M. , Martin , L. , McCulloch , P. , Pezzella , F. , Viale , G. , Weidner , N. , Harris , A. L. and Dirix , L. Y.Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation . Eur. J. Cancer , 32A , 2474 – 2484 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Yamaoka , M. , Yamamoto , T. , Masaki , T. , Ikeyama , S. , Sudo , K. and Fujita , T.Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O‐(chloroacetyl‐carbamoyl)fumagillol (TNP‐470; AGM‐1470) . Cancer Res 53 , 4262 – 4267 ( 1994. ). [PubMed] [Google Scholar]
  • 22. ) O'Reilly , M. S. , Holmgren , L. , Shing , Y. , Chen , C. , Rosenthal , R. A. , Moses , M. , Lane , W. S. , Cao , Y. , Sage , E. H. and Folkman , J.Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma . Cell , 79 , 315 – 328 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 23. ) Hong , W. K. and Itri , L. M.Retinoids and human cancer . In “ The Retinoids: Biology, Chemistry, and Medicine, Second Edition ,“ ed. Sporn M. B. , Roberts A. B. and Goodman D. S. , pp. 597 – 630 ( 1994. ). Raven Press; , New York . [Google Scholar]
  • 24. ) Lingen , M. W. , Polverini , P. J. and Bouck , N. P.Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells . Lab. Invest 74 , 476 – 483 ( 1996. ). [PubMed] [Google Scholar]
  • 25. ) Muindi , J. , Frankel , S. R. , Miller , W. H. , Jr. , Jakubowski , A. , Scheinberg , D. A. , Young , C. W. , Dmitrovsky , E. and Warrell , R. P. , Jr.Continuous treatment with all‐trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia . Blood 79 , 299 – 303 ( 1992. ). [PubMed] [Google Scholar]
  • 26. ) Muindi , J. R. R , Frankel , S. R. , Huselton , C. , DeGrazia , R , Garland , W. A. , Young , C. W. and Warrell , R. P. , Jr.Clinical pharmacology of oral all‐trans retinoic acid in patients with acute promyelocytic leukemia . Cancer Res 52 , 2138 – 2142 ( 1992. ). [PubMed] [Google Scholar]
  • 27. ) Kohn , E. C. and Liotta , L. A.Molecular insights into cancer invasion: strategies for prevention and intervention . Cancer Res 55 , 1856 – 1862 ( 1995. ). [PubMed] [Google Scholar]
  • 28. ) Klauber , N. , Browne , R , Anand‐Apte , B. and D'Amato , R. J.New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo . Circulation 94 , 2566 – 2571 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Kerbel , R. S.A cancer therapy resistant to resistance . Nature 390 , 335 – 336 ( 1997. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES